Arca
Skip to content
Tools
Tools

KCNJ11: ATP-sensitive inward rectifier potassium channel 11

Inward rectifier potassium channel that forms the pore of ATP-sensitive potassium channels (KATP), regulating potassium permeability as a function of cytoplasmic ATP and ADP concentrations in many different cells.

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on KCNJ11, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1

Approved1

  • Diazoxide

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        DiazoxideApprovedMerck & Co. (MSD)Small moleculeOpenerPotassium channel, inwardly rectifying, subfamily J, member 11 opener5

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 5 in all, from ClinicalTrials.gov.
        Diazoxide in the Treatment of Type 1 GlycogenosisDiazoxide—Not yet recruitingCentral Hospital, Nancy, FranceJul 31, 2026
        Observational Study of VYKAT™ XR in Patients With Prader-Willi SyndromeDiazoxide—Enrolling by invitationSoleno Therapeutics, Inc.Mar 5, 2026
        Effect of Insulin Lowering on LipogenesisDiazoxidePhase 1RecruitingColumbia UniversityFeb 11, 2026
        Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)Diazoxide—RecruitingDuke UniversityFeb 20, 2020
        Regulation of Endogenous Glucose Production by Central KATP ChannelsDiazoxidePhase 2RecruitingAlbert Einstein College of MedicineMay 30, 2018

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        • Type 2 diabetes mellitus0.88
        • Hyperinsulinemic hypoglycemia, familial, 20.84
        • Diabetes mellitus, permanent neonatal 20.81
        • Diabetes mellitus, transient neonatal, 30.80
        • Transient neonatal diabetes mellitus0.72
        • Permanent neonatal diabetes mellitus0.71
        • Maturity-onset diabetes of the young0.70
        • Autosomal dominant hyperinsulinism due to Kir6.2 deficiency0.69
        • Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency0.69
        • Hypertensive disorder0.68
        • Familial hyperinsulinism0.66

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1886, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q14654, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.